S
KROS icon

Sachetta’s Keros Therapeutics KROS Stock Holding History

Sachetta’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
244
– – ﹤0.01% 804
2026
Q1 		$2.69K Hold
244
– – ﹤0.01% 823
2025
Q4 		$4.97K Hold
244
– – ﹤0.01% 549
2025
Q3 		$3.86K Hold
244
– – ﹤0.01% 665
2025
Q2 		$3.26K Hold
244
– – ﹤0.01% 689
2025
Q1 		$2.49K Sell
244
-244
-50% -$2.83K ﹤0.01% 733
2024
Q4 		$7.73K Hold
488
– – ﹤0.01% 496
2024
Q3 		$28.3K Hold
488
– – 0.01% 328
2024
Q2 		$25.1K Hold
488
– – 0.01% 313
2024
Q1 		$19.4K Hold
488
– – 0.01% 312
2023
Q4 		$19.4K Buy
+488
New +$15.3K 0.01% 312

Other funds holding KROS

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Sachetta's KROS Position: Q2 2026 in Review

Sachetta held its Keros Therapeutics (KROS) position steady in Q2 2026 at 244 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #804.

Sachetta first reported a position in KROS in Q4 2023 and has held it in 11 quarters since. The position peaked at $28.3K in Q3 2024. 7 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Sachetta held 244 shares of Keros Therapeutics worth $2.61K as of Q2 2026.
  • Sachetta left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Sachetta's portfolio in Q2 2026, its #804 holding.
  • Sachetta first reported a position in Keros Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Sachetta's Keros Therapeutics position peaked at $28.3K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.